发明名称 HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS
摘要 The invention provides a compound of Formula (I);;pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
申请公布号 US2014162985(A1) 申请公布日期 2014.06.12
申请号 US201314019980 申请日期 2013.09.06
申请人 Burchat Andrew;Gordon Thomas D.;Mullen Kelly D.;Ihle David C.;Morytko Michael J.;Cusack Kevin P.;Lo Schiavo Gloria Y.;Wang Lei;Friedman Michael 发明人 Burchat Andrew;Gordon Thomas D.;Mullen Kelly D.;Ihle David C.;Morytko Michael J.;Cusack Kevin P.;Lo Schiavo Gloria Y.;Wang Lei;Friedman Michael
分类号 C07F9/6503;C07D401/06;C07D471/04;C07D401/14;C07D491/044;C07D231/54;C07D417/08 主分类号 C07F9/6503
代理机构 代理人
主权项 1. A compound of Formula (I): or a pharmaceutically acceptable salt, pro-drug, biologically active metabolite, isomer, or stereoisomer thereof, wherein: Ring A′ is a heteroaryl ring or an unsaturated or partially unsaturated heterocyclic ring, wherein: G is S, O, CR1, C(R1)2, N, or NR1;J is C, CR1, C(R1)2, O, N, or NR1; and,L is C, CR1, C(R1)2, N, or NR1;provided that J is not O if G is O or S; and,Ring A is an optionally substituted pyrazine, optionally substituted pyridine, or optionally substituted phenyl;Ring B is a seven-membered ring optionally substituted with deuterium, wherein: X is —C(R5)2—, —C(R5)═, —C(═O)—, —N(Ra)—, —O—, —S—, —S(O)—, or —S(O)2—; orwhen X is —C(R5)2—, both R5 substituents, together with the carbon atom to which they are attached, optionally forms a cyclopropyl ring spiro to Ring B;Y is —C(R5)2C(R5)2—, ═C(R5)C(R5)2—, —C(R5)2C(R5)═, ═C(R5)C(R5)═, —N(Ra)C(R5)2—, —C(R5)2N(Ra)—, —C(═O)C(R5)2—, —C(R5)2C(═O)—, —O—C(═O)—, —C(═O)—O—, —OC(R5)2—, or —C(R5)2—O—; provided that X—Y does not form —N(Ra)—C(R5)2—N(Ra)—, —S—C(R5)2—N(Ra)—, —S—C(R5)2—O—, —O—C(R5)2—N(Ra)—, —C(═O)—C(═O)—C(R5)2—, —C(═O)—C(═O)—O—, —N(Ra)—C(R5)2—O—, —O—C(R5)2—O—, —S—C(═O)C(R5)2—, —S—C(═O)—O—, or —S—C(R5)2—O— bonds; andprovided that X—Y does not result in an oxygen atom adjacent to either a nitrogen atom, a sulfur atom or another oxygen atom; andprovided that X—Y does not result in two nitrogen atoms adjacent to one another;Ring C is an optionally substituted, saturated or partially unsaturated, five- or six-membered carbocyclyl or heterocyclyl ring;R1 is independently H, deuterium, —Br, —Cl, —F, —CF3, —CN, —ORb, -optionally substituted (C1-C3)alkylene-Rb, optionally substituted (C1-C3)alkyl, optionally substituted aryl, optionally substituted (C3-C6)cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, —S(O)2Rb—, ═O, or —N(Ra)(Rb);R1a is independently H, deuterium, —Br, —Cl, —F, —CF3, —CN, optionally substituted (C1-C6)alkyl, optionally substituted (C3-C6)cycloalkyl, optionally substituted heterocyclyl, —S(O)2—Ra, or —N(Ra)2;R2 is —CD3, —CH2CD3, —CN, -allyl, —CH2NHC(═O)(C1-C3)alkyl, —CH2NHSO2(C1-C3)alkyl, —N(R)—SO2-optionally substituted alkyl; —N(R)(Rg), —N(R)-optionally substituted cycloalkyl, —N(R)-optionally substituted aryl, —N(R)-optionally substituted heteroaryl, —N(R)-optionally substituted heterocyclyl, —N(R)C(O)-optionally substituted alkyl, —N(R)2, —C(O)N(Ra)2, —CH2-optionally substituted aryl, —CH2-optionally substituted (C3-C6)cycloalkyl, optionally substituted (C1-C3)alkyl, optionally substituted (C2-C3)alkenyl, —CH2-optionally substituted heteroaryl, —(CH2)n1-optionally substituted heterocyclyl, —C(Rd)2—Re, or —C(═O)—Re, provided that when R2 is —C(Rd)2—Re, only one Rd can be OH;R3 is independently a bond, deuterium, —CD3, —CF3, —N(Ra)SO2Rc, —N(Ra)CORc, —CON(Ra)Rc, —N(Ra)COORc, —N(Ra)2, —O—C(O)NR-optionally substituted alkyl, optionally substituted (C2-C6)alkynyl, ═O, —ORa, —ORf, optionally substituted (C1-C4)alkyl, optionally substituted (C1-C4)alkyl-O—(C1-C4)alkyl, —(C(Ra)2)r-optionally substituted (C3-C6)cycloalkyl, —(C(Ra)2)r-optionally substituted aryl, —(C(Ra)2)r-optionally substituted heteroaryl, —(C(Ra)2)r—N(Ra)-optionally substituted heteroaryl, —(C(Ra)2)r—N(Ra)—(C(Ra)2)r-optionally substituted aryl, or a carbocyclic or heterocyclic spirocyclic moiety attached to ring C;R4 is a bond, H, deuterium, —CD3, —F, optionally substituted (C1-C3)alkyl, —OH or —O-optionally substituted (C1-C3)alkyl;R5 is independently H, deuterium, —CD3, —F, —CF3, —N(Ra), —ORa, or optionally substituted (C1-C3)alkyl; and,Ra is independently H, deuterium, optionally substituted (C3-C6)cycloalkyl, or optionally substituted (C1-C3)alkyl;Rb is H, optionally substituted (C1-C3)alkyl, optionally substituted aryl, optionally substituted (C3-C6)cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;Rc is optionally substituted (C1-C3)alkyl or optionally substituted aryl;Rd is independently H, deuterium, —OH, or optionally substituted (C1-C6) alkyl;Re is —CF3, optionally substituted aryl, optionally substituted (C1-C6)alkyl, optionally substituted (C3-C6)cycloalkyl, optionally substituted heteroaryl, or optionally substituted heterocyclyl;Rf is —H, —SO2NH2, —CH2CO2H, —CH2CONH2, —P(═O)(OH)(OH), —C(O)-optionally substituted(C1-C6) alkyl, —C(O)N(optionally substituted (C1-C6)alkyl)2, —C(O)(optionally substituted (C1-C6)alkyl)2, —C(O)-optionally substituted aryl, —C(O)-optionally substituted heterocyclyl, —C(O)-optionally substituted (C3-C6)cycloalkyl, —C(O)—CR2-optionally substituted heterocyclyl or C(O)—CR2-optionally substituted heteroarylRg is —CH2-optionally substituted (C3-C6)cycloalkyl, —CH2-optionally substituted heteroaryl, or —CH2-optionally substituted heterocyclyl;R is independently H or (C1-C3)alkyl;m is 0, 1, or 2;n1 is independently 0 or 1;p is 1, 2, 3 or 4; andr is independently 0, 1 or 2.
地址 Shrewsbury MA US